Mesoblast (MESO) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mesoblast’s allogeneic cell therapy, Revascor, has shown promising results in improving survival and reducing major cardiovascular events in high-risk ischemic heart failure patients with inflammation, according to a recent study. The therapy significantly lowered the risk of cardiovascular death and major adverse cardiovascular events, highlighting its potential as a disease-modifying treatment. This breakthrough could position Mesoblast favorably in the market as they seek approval for broader application of their heart failure product.
For further insights into MESO stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “More Hopeful than Real”: Is a Bidding War Brewing for Warner Bros. Discovery Stock (NASDAQ:WBD)?
- “Didn’t Develop the Way Automakers Thought.” Ford Notches Up, Reconsidering the EV Market
- “Our Focus is Increasingly…on Inference”: Intel Stock (NASDAQ:INTC) Jumps With Crescent Island Testing Next Year